Febuxostat Superior to Allopurinol for Prevention of Tumor Lysis Syndrome

Share this content:
Febuxostat achieved a significant serum uric acid control in patients with hematologic malignancies at tumor lysis syndrome risk.
Febuxostat achieved a significant serum uric acid control in patients with hematologic malignancies at tumor lysis syndrome risk.

Febuxostat achieved a significant serum uric acid control with one fixed dose compared with allopurinol with comparable renal function preservation and safety profile in patients with hematologic malignancies at intermediate to high tumor lysis syndrome risk, a new study published online ahead of print in the journal Annals of Oncology has shown.

Serum uric acid level correlated with both tumor lysis syndrome and risk for renal events. Allopurinol is typically given to patients at risk for developing tumor lysis syndrome in order to prevent complications like acute kidney failure.

In this double-blind, phase 3 trial, researchers enrolled 346 patients with hematologic malignancies at intermediate-to-high tumor lysis syndrome risk and randomly assigned them to receive febuxostat 120 mg or allopurinol 200-600 mg. Uric acid-lowering drugs were initiated 2 days prior to induction chemotherapy, for 7 to 9 days.

Results showed that febuxostat significantly reduced serum uric acid levels compared with allopurinol (P<0.0001).

RELATED: Copy Number Alterations Independently Associated with Prognosis for Acute Leukemia

In addition, both drugs achieved similar renal function preservation (P=0.0903). No differences in treatment responder rate tumor lysis syndrome incidence and safety were observed.

In regard to drug safety, drug-related adverse events were reported in 6.4% of patients in both treatment arms.

Reference

  1. Spina M, Nagy Z, Ribera JM, et al. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015. [epub ahead of print]. doi: 10.1093/annonc/mdv317.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters